| Project/Area Number |
26670467
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Ehime University |
|---|
Principal Investigator |
Yasukawa M 愛媛大学, 医学(系)研究科(研究院), 教授 (60127917)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | がん免疫療法 / 細胞傷害性T細胞 / ADCC活性 / キメラ遺伝子 / CD16 / CAR-T / TCR-T / 遺伝子治療 / chimeri antigen receptor / 悪性リンパ腫 / 細胞障害性T細胞 / 抗体療法 / ADCC |
|---|
| Outline of Final Research Achievements |
The antibody therapy against malignancies depends on antibody-dependent cell-mediated cytotoxicity (ADCC). ADCC is mediated by NK cells expressing CD16 on their cell surface; however, T cells cannot exert any ADCC activity, since they are negative for CD16 expression. In this study, we attempted to produce CD16-CD3z chimeric gene and to transduce it into activated CD8-positive T cells. CD16-CD3z T cells showed high ADCC activity in the presence of antibody in vitro. In addition, it was shown that the combination therapy of CD16-CD3z T cells and antibody against the cell surface molecule of malignant cells exerted anti-tumor activity in human tumor-transplanted immune-deficient mice.
|
